Jacob Glanville is a serial entrepreneur and computational immuno-engineer. He is also the founder, CEO, & President of Centivax. He was formerly a Co-founder, CEO, and President of Distributed Bio, which he and his co-founders sold to Charles River Laboratories in 2020. During his time at Distributed Bio, he developed the core business model, research teams, and technologies that enabled the company to become profitable without investment.
As part of the acquisition agreement, he founded Centivax Inc and spun-out his assets in COVID-19 therapeutics, broad-spectrum vaccines, anti-venom antibodies, anti-wound pathogen antibodies, anti-CXCR5 autoimmunity therapeutics, and blood-brain barrier translation technologies into Centivax.
.png)
How to Choose the Right Venture Capital Partner | Fundraising as “Dating” | Finding Proper Alignment & The Win-Win | VC Network as a “Polishing Engine”
Building a Biotech without Venture Capital | Picking Lab Space & Company Growth | Equipment Leasing & Runway/Cash Flow Maximization | Process Drift & “The Respiration Model
Creating Bioinformatic Tools | Innovation vs. Organization in Biotech Companies | Finding Excitement in Your Work | Tech Transfer & “Separation of Church and State
Hospitality Industry’s Applied Lessons | The Benefits of Contingency Planning & Fair Negotiation | How to Seek Translational Skill Sets & Cross Training
Start listening to TBSP episodes on your favorite platform. Subscribe to stay up to date on new episodes.
